Abstract
Vaccination and administration of monoclonal antibody cocktails are effective tools to control the progression of infectious diseases and to terminate pandemics such as COVID-19. However, the emergence of SARS-CoV-2 mutants with enhanced transmissibility and altered antigenicity requires broad-spectrum therapies. Here we developed a panel of SARS-CoV-2 specific mouse monoclonal antibodies (mAbs), and characterized them based on ELISA, Western immunoblot, isotyping, and virus neutralization. Six neutralizing mAbs that exhibited high-affinity binding to SARS-CoV-2 spike protein were identified, and their amino acid sequences were determined by mass spectrometry. Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.
Keywords: Broad-spectrum neutralizing mAbs; PRNT; SARS-CoV-2; Variant of concern (VOC).
【저자키워드】 SARS-CoV-2, PRNT, Broad-spectrum neutralizing mAbs, variant of concern (VOC), 【초록키워드】 COVID-19, Vaccine, mass spectrometry, therapy, Infectious diseases, antibody, VoC, B.1.351, monoclonal antibody, variant, variants of concern, B.1.617.2, Infectious disease, progression, monoclonal antibodies, ELISA, Spike protein, Transmissibility, B.1.1.7, P.1, SARS-CoV-2 spike protein, Virus neutralization, Pandemics, Alpha, Beta, Neutralizing, COVID-19 therapy, antigenicity, mouse monoclonal antibody, Therapies, mAbs, PRNT, mAb, Amino acid, Interaction, administration, amino acid sequence, determined by, (Beta), (Alpha), Support, Candidates, Amino acid sequences, candidate, SARS-CoV-2 mutants, virus spike protein, high-affinity binding, immunoblot, effective, neutralized, exhibited, characterized, SARS-CoV-2 mutant, 【제목키워드】 development,